Interesting. Thanks. I took a look back through recent Medivir presentation slides and slide 29 from the 5/8/12 CC references treating cirrhotic patients in newer IFN-free combo regimens. The point made is that the newer IFN-free combos have just been testing easier to treat non-fibrotic patients and that when fibrotic patients have been included, the SVR rate drops dramatically. Medivir has hope that this will be different with TMC435 included in IFN-free combos given its prior strong results in cirrhotic patients. Medivir also notes that TMC435 triple therapy is the only therapy that has been shown to deliver high cure rates for the most-difficult-to-treat cirrhotic patients in both treatment naive and treatment experienced patients. Pretty strong statement there. Do you disagree with that statement?
Market Data 
Markets 
AI
